AIMS: The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined. METHODS AND RESULTS: We assessed SCD and ventricular arrhythmias in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, which included patients with acute HF with reduced or preserved ejection fraction. SCD, resuscitated SCD (RSCD), and sustained ventricular tachycardia/ventricular fibrillation (VT/VF) were adjudicated from randomization through 30 days and were combined into a composite endpoint. Baseline characteristics associated with this composite were determined by logistic regression. RSCD and VT/VF were included as time-dependent variables in a Cox model evaluating the association of these variables with 180-day all-cause mortality. Among 7011 patients, the 30-day all-cause mortality rate was 3.8%; SCD accounted for 17% of these deaths. The 30-day composite event rate was 1.8% (n = 121). Ten patients had more than one event with 30-day Kaplan-Meier event rates of 0.6% for SCD [95% confidence interval (CI) 0.5%-0.9%, n = 43], 0.4% for RSCD (95% CI 0.2%-0.5%, n = 24), and 0.9% for VT/VF (95% CI 0.7%-1.2%, n = 64). In the multivariable model, chronic obstructive pulmonary disease, history of VT, male sex, and longer QRS duration were associated with SCD, RSCD, or VT/VF. A RSCD or VT/VF event was associated with higher 180-day mortality (adjusted hazard ratio 6.6, 95% CI 4.8-9.1, P < 0.0001). CONCLUSIONS: Approximately 2% of patients admitted for acute HF experienced SCD, RSCD, or VT/VF within 30 days of admission, and SCD accounted for 17% of all deaths within 30 days.
RCT Entities:
AIMS: The incidence of and factors associated with sudden cardiac death (SCD) early after an acute heart failure (HF) hospital admission have not been well defined. METHODS AND RESULTS: We assessed SCD and ventricular arrhythmias in the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial, which included patients with acute HF with reduced or preserved ejection fraction. SCD, resuscitated SCD (RSCD), and sustained ventricular tachycardia/ventricular fibrillation (VT/VF) were adjudicated from randomization through 30 days and were combined into a composite endpoint. Baseline characteristics associated with this composite were determined by logistic regression. RSCD and VT/VF were included as time-dependent variables in a Cox model evaluating the association of these variables with 180-day all-cause mortality. Among 7011 patients, the 30-day all-cause mortality rate was 3.8%; SCD accounted for 17% of these deaths. The 30-day composite event rate was 1.8% (n = 121). Ten patients had more than one event with 30-day Kaplan-Meier event rates of 0.6% for SCD [95% confidence interval (CI) 0.5%-0.9%, n = 43], 0.4% for RSCD (95% CI 0.2%-0.5%, n = 24), and 0.9% for VT/VF (95% CI 0.7%-1.2%, n = 64). In the multivariable model, chronic obstructive pulmonary disease, history of VT, male sex, and longer QRS duration were associated with SCD, RSCD, or VT/VF. A RSCD or VT/VF event was associated with higher 180-day mortality (adjusted hazard ratio 6.6, 95% CI 4.8-9.1, P < 0.0001). CONCLUSIONS: Approximately 2% of patients admitted for acute HF experienced SCD, RSCD, or VT/VF within 30 days of admission, and SCD accounted for 17% of all deaths within 30 days.
Authors: Muthiah Vaduganathan; Ravi B Patel; Robert J Mentz; Haris Subacius; Neal A Chatterjee; Stephen J Greene; Andrew P Ambrosy; Aldo P Maggioni; James E Udelson; Karl Swedberg; Marvin A Konstam; Christopher M O'Connor; Javed Butler; Mihai Gheorghiade; Faiez Zannad Journal: Am J Cardiol Date: 2018-04-11 Impact factor: 2.778
Authors: Andrew P Ambrosy; Craig S Parzynski; Daniel J Friedman; Marat Fudim; Adrian F Hernandez; Gregg C Fonarow; Frederick A Masoudi; Sana M Al-Khatib Journal: Circulation Date: 2018-12-11 Impact factor: 29.690
Authors: João Pedro Ferreira; Abhinav Sharma; Cyrus Mehta; George Bakris; Patrick Rossignol; William B White; Faiez Zannad Journal: Clin Res Cardiol Date: 2020-08-13 Impact factor: 5.460
Authors: Sarah A Goldstein; Robert J Mentz; Anne S Hellkamp; Tiffany C Randolph; Gregg C Fonarow; Adrian Hernandez; Clyde W Yancy; Sana M Al-Khatib Journal: Clin Cardiol Date: 2018-12-26 Impact factor: 2.882
Authors: Piotr Ponikowski; Ilaria Spoletini; Andrew J S Coats; Massimo F Piepoli; Giuseppe M C Rosano Journal: Eur Heart J Suppl Date: 2019-12-31 Impact factor: 1.803
Authors: Tomás Benito-González; Xavier Freixa; Cosmo Godino; Maurizio Taramasso; Rodrigo Estévez-Loureiro; Daniel Hernandez-Vaquero; Ana Serrador; Luis Nombela-Franco; David Grande-Prada; Ignacio Cruz-González; Rodolfo San Antonio; Michele Galasso; Mara Gavazzoni; Carmen Garrote; Antonio Portolés-Hernández; Pablo Avanzas; Felipe Fernández-Vázquez; Isaac Pascual Journal: Ann Transl Med Date: 2020-08